Upregulation of NFS1 and downregulation of GSDMD as prognostic biomarkers in acute myeloid leukemia: implications for diagnosis and therapeutic strategies
Authors:
- Sara M. RadwanSRSara M. Radwan
- Dina MostafaDMDina Mostafa
- Rania A. RadwanRRRania A. Radwan
- Hany A. ElghobaryHEHany A. Elghobary
- Wesam R. ElghamryWEWesam R. Elghamry
- Amany M. KamalAKAmany M. Kamal
Open Access
- 9 June 2026
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Abstract
Despite advances in the treatment of Acute Myeloid Leukemia (AML), the predictive 5-year overall survival rate is still poor not exceeding 20%. Most patients develop relapse partly due to resistance mechanisms to classical cell death programs. Currently, cytogenetic markers play a crucial role in the early diagnosis, prognostic classification, and therapy selection for AML. Yet, there is a pressing need for the discovery of novel AML biomarkers for a better understanding of the disease’s molecular mechanisms, diagnosis, prognosis assessment, and personalized therapeutic response. The role of cell death-related genes in driving AML progression and spread remains inadequately explored. Among these, ferroptosis and pyroptosis are emerging as critical mechanisms of programmed cell death that are often dysregulated in cancer. We recruited 100 newly diagnosed AML patients and 40 healthy matched individuals. Using reverse transcription-quantitative PCR analysis, we assessed the expression levels of NFS1 and Gasdermin D (GSDMD). Our findings revealed significant NFS1 upregulation (P < 0.0001) and GSDMD downregulation (P < 0.0001) in AML patients compared to healthy controls. Following treatment, we observed a significant downregulation of NFS1 expression (P < 0.001) and upregulation of GSDMD (P < 0.001). Furthermore, higher pretreatment levels of NFS1 and lower pretreatment levels of GSDMD correlated with poor prognosis (P < 0.001) and decreased one-year survival (P < 0.001). Our study suggests that NFS1 and GSDMD may serve as early diagnostic and prognostic markers in AML, offering potential targets for improved therapeutic strategies.Keywords
This publication has 71 references indexed in Scilit:
- Research Progress on Pyroptosis in Hematological MalignanciesCurrent Treatment Options in Oncology, 2023
- Pyroptosis-related gene expression patterns and corresponding tumor microenvironment infiltration characterization in ovarian cancerComputational and Structural Biotechnology Journal, 2022
- Comprehensive analysis of a pyroptosis-related gene signature of clinical and biological value in acute myeloid leukaemiaInternational Immunopharmacology, 2022
- Hyperactive CDK2 Activity in Basal-like Breast Cancer Imposes a Genome Integrity Liability that Can Be Exploited by Targeting DNA Polymerase εMolecular Cell, 2020
- Typhaneoside prevents acute myeloid leukemia (AML) through suppressing proliferation and inducing ferroptosis associated with autophagyBiochemical and Biophysical Research Communications, 2019
- Targeting Ferroptosis to Iron Out CancerCancer Cell, 2019
- Inhibition of Dpp8/9 Activates the Nlrp1b InflammasomeCell Chemical Biology, 2018
- Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid LeukemiaCancer Cell, 2017
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001